James Gulley
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name James Gulley as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04847050 · A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyNational Cancer Institute (NCI) · completed · Solid Tumor Malignancy, Hematologic Malignancy, Leukemia · principal investigator
- Ph2NCT04538378 · Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsNational Cancer Institute (NCI) · terminated · EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine · principal investigator
- Ph1/Ph2NCT04209595 · PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell CancersNational Cancer Institute (NCI) · completed · Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas · principal investigator
- Ph2NCT01838642 · Ponatinib for Advanced Medullary Thyroid CancerNational Institutes of Health Clinical Center (CC) · terminated · Thyroid Neoplasms · principal investigator
- Ph1/Ph2NCT01240590 · A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)National Cancer Institute (NCI) · completed · Solid Tumor, Anaplastic Thyroid Cancer · principal investigator
- N/ANCT00535834 · Studying Stored Samples From Patients With Localized Prostate Cancer Treated on Clinical Trial NCI-00-C-0154National Institutes of Health Clinical Center (CC) · completed · Prostate Cancer · principal investigator
- Ph2NCT00007345 · Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaNational Cancer Institute (NCI) · completed · Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Basic Research Support for the CCRZICBC011021 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $2,282,526 awarded in 2025Same name and institution; not confirmed by an ID
- Bench to Beside and Back translational immuno-onocology-CuresZIABC012128 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 to 2025 · $50 awarded in 2025Same name and institution; not confirmed by an ID
- Cancer ImmunotherapyZIABC010666 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $4,841,882 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical Research Support for the CCRZIDBC011022 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $2,522,792 awarded in 2025Same name and institution; not confirmed by an ID
- Developing Tumor Infiltrating Lymphocyte Therapy for Patients with HIV and CancerZIABC012198 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2025 · $143,907 awarded in 2025Same name and institution; not confirmed by an ID
- Office of Sponsor and Regulatory OversightZIDBC011875 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2025 · $18,493,892 awarded in 2025Same name and institution; not confirmed by an ID
- Office of Translational ResourcesZICBC011933 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 to 2025 · $1,201,329 awarded in 2025Same name and institution; not confirmed by an ID
- CCR Office of Training and EducationZIJBC011133 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2024 · $160,787 awarded in 2024Same name and institution; not confirmed by an ID
- NCI-Alliance immune-related Adverse Events (irAE) Biorepository-CuresZIABC012160 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2023 · $191,131 awarded in 2023Same name and institution; not confirmed by an ID
- T-Cell Receptor Gene Therapy for Human Cancers-CuresZIABC011871 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2021 to 2023 · $33,240 awarded in 2023Same name and institution; not confirmed by an ID
- Cellular TherapyZIABC012067 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2022 · $286,212 awarded in 2022Same name and institution; not confirmed by an ID
- Clinical trials employing cancer vaccine combination therapiesZIABC010945 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2022 · $715,531 awarded in 2022Same name and institution; not confirmed by an ID
- Medical Oncology HIV-AIDS Clinical ResearchZIDBC011683 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2016 to 2021 · $398,401 awarded in 2021Same name and institution; not confirmed by an ID
- Medical Oncology Service Clinical CoreZIDBC011543 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2021 · $2,257,611 awarded in 2021Same name and institution; not confirmed by an ID
- Medical Oncology Fellowship ProgramZIEBC010843 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2014 to 2015 · $6,114,523 awarded in 2015Same name and institution; not confirmed by an ID
- Cancer Therapy Clinical Trials Using Novel Recombinant VaccinesZ01BC010666 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2005 to 2008 · $517,380 awarded in 2008Same name and institution; not confirmed by an ID
- Clinical trials employing cancer vaccine combination therapiesZ01BC010945 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2008 · $517,380 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 130 PubMed records, and a shared surname and initials can bring in a namesake. All 130 on PubMed
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.J Clin Oncol · 2010769 citationsRCR 17.5
- Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.J Clin Oncol · 2017486 citationsRCR 15.1
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.Lancet Oncol · 2018473 citationsRCR 15.1
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.JAMA Oncol · 2019397 citationsRCR 13.6
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.Clin Cancer Res · 2018362 citationsRCR 11.2
- Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.Clin Cancer Res · 2005282 citationsRCR 5.3
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.Lancet Oncol · 2012271 citationsRCR 6.6
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.J Clin Oncol · 2004250 citationsRCR 5.1
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.Lancet Oncol · 2017247 citationsRCR 7.5
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors.J Immunother Cancer · 2019241 citationsRCR 8.6